Non-stimulant ADHD medications, such as atomoxetine and guanfacine, provide effective alternatives to stimulants, addressing ...

and guanfacine. Atomoxetine, which is usually marketed under the brand name Strattera, was the first non-stimulant ADHD medication to be approved by the FDA in 2002. It isn't clear how atomoxetine ...

He is currently on the medication Guanfacine. Ms McAnish said: "Unlike some medications that can be started or stopped at will, it's specifically advised not to stop [Guanfacine] abruptly." ...

Onyda XR contains an ER formulation of clonidine. It is FDA-approved to treat ADHD alone or in combination with a stimulant ...

The page includes both the generic and brand names and can serve as an invaluable resource for healthcare professionals and individuals who wish to get an insight on different medication options.

Medication is not the only treatment, but it is often the treatment that can make ... There are also non-stimulants, in particular atomoxetine and guanfacine, which are used less often but can also be ...

A new Review article series, “AI in Medicine,” explores the role of AI technology in clinical medicine and digital health, and examines the promise and pitfalls of its application across the ...

Communications Medicine is a selective open access journal from Nature Portfolio publishing high-quality research, reviews and commentary across all clinical, translational and public health ...

Apr. 30, 2024 — A genetic propensity to higher circulating levels of lipids containing arachidonic acid, an omega-6 polyunsaturated fatty acid found in eggs, poultry, and seafood, has been found ...

The Race and Medicine collection reflects NEJM’s commitment to understanding and combating racism as a public health and human rights crisis. Our commitment to antiracism includes efforts to ...

The Correspondence section provides a forum for discussion or to present a point of view on issues that are of interest to the readership of Nature Medicine. Correspondences should not contain new ...